Fig. 3.

Characterization of LC3 modification after infection. (A) HFFF2 monolayers were mock infected or infected with HCMV AD169 (CMV), gradient-purified HCMV AD169 (Pure), or UV-HCMV (uv) in the absence or continuous presence of 100 μg of cycloheximide (CH) per milliliter. Cell lysates were prepared at 6 hpi for the analysis of LC3. (B) HFFF2 monolayers were mock infected (M) or infected with HCMV AD169 (CMV) or HSV-1 in1312 (HSV) and incubated at 38.5°C in the absence or continuous presence of CH. Cell lysates were prepared for the analysis of LC3 at 6 hpi. (C) HFFF2 monolayers were mock infected (M) or infected with HCMV strain Merlin (Mer) or AD169 (AD) in the absence or continuous presence of CH. Cell lysates were prepared for the analysis of LC3 at 6 hpi. (D) HFFF2 monolayers were mock infected or infected with UV-HCMV (uvCMV), UV-irradiated RSV (uvRSV), or untreated RSV. Cell lysates were prepared for the analysis of LC3 at 7 hpi (lanes 1 to 4) or 24 hpi (lanes 5 to 8). (E) HFFF2 monolayers were mock treated for 3 h (M), treated with 3 mM MβCD for 2 h, or infected with UV-HCMV for 3 h in the absence (lanes 1 to 3) or presence (lanes 4 to 6) of 10 mM NH₄Cl. Cell lysates were prepared for the analysis of LC3.